Mirena Articles
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
Bayer's 2nd-qtr 2008 net profit falls 13%
11 August 2008
Bayer's 4th-qtr 2007 profit plummets 76% to 67M euros, well below analyst expectations
10 March 2008
Bayer Schering's Mirena cleared in Japan
12 February 2007
Takeover costs impact Schering AG's 1st-half 2006
31 July 2006
Takeover costs impact Schering's 1st-half 2006
26 July 2006
Schering AG sees 2005 net leap 23%
27 February 2006
Schering AG raises 2004 forecast on 2nd-qtr
2 August 2004
Schering AG's 1st-qtr beats expectations
3 May 2004
UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook
16 February 2004
Schering AG sees strong profit growth
3 November 2003
Profits and sales down at Schering AG
11 August 2003
Schering AG beats forecasts in 2002
10 March 2003
Update: Sales up 11% at Schering AG
10 March 2003
Schering AG's 2002 sales disappoint
10 February 2003
Schering AG US sales up 22% in Q2
5 August 2002
Schering AG CEO optimistic about firm's future prospects
22 April 2002
Leiras Oy offers technology for drug delivery
15 April 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Schering's Mirena cleared in USA
7 December 2000
1999 sales and profits up at Schering AG - updated story
10 February 2000
Schering AG sales up 9% for 1st nine months
11 November 1999
Schering sales growth driven by Betaferon
11 August 1999
Schering sales growth driven by Betaferon
6 August 1999
Schering AG looking to list in the USA
4 May 1999
Europe/US sales offset Asian crisis at Schering
9 February 1999
Schering AG Profits Impacted By Asian Crisis
10 August 1998
Strong Start To 1998 By Schering AG
5 May 1998
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Schering AG To Buy Huhtamaki's Leiras Unit
22 July 1996
UK Industry Code of Practice: latest Report
4 March 1996
Profits Lower Than Expected At Huhtamaki
16 October 1995
Showing 1-49 of 49 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
